Regardless of shorting or bashing, we still gotta

Regardless of shorting or bashing, we still gotta admire Jounce Therapeutics's key negotiator(s) who managed to nab a superb deal with Celgene of $225 mil upfront payment and equity investment of $36 mil for a pre-clinical cancer drug! Yup, pre-clinical, not even in clinical trials yet! Do note that Jounce Therapeutics is privately held (not listed in any public market), so bashing and shorting are not possible, ha!

http://www.fiercebiotech.com/biotech/jounce-n...up-celgene